Leerink Partnrs Analysts Lower Earnings Estimates for ACAD

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Investment analysts at Leerink Partnrs lowered their Q2 2025 earnings per share (EPS) estimates for shares of ACADIA Pharmaceuticals in a research report issued on Wednesday, May 7th. Leerink Partnrs analyst M. Goodman now anticipates that the biopharmaceutical company will earn $0.16 per share for the quarter, down from their previous forecast of $0.21. The consensus estimate for ACADIA Pharmaceuticals' current full-year earnings is $0.70 per share. Leerink Partnrs also issued estimates for ACADIA Pharmaceuticals' FY2025 earnings at $0.55 EPS and FY2029 earnings at $2.15 EPS.

Several other research analysts have also recently weighed in on the company. HC Wainwright reiterated a "buy" rating and set a $27.00 price target on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. Cantor Fitzgerald reiterated an "overweight" rating and set a $28.00 target price on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. Needham & Company LLC reissued a "buy" rating and issued a $28.00 price target on shares of ACADIA Pharmaceuticals in a report on Tuesday, April 8th. Morgan Stanley restated an "equal weight" rating and set a $20.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Friday, March 7th. Finally, StockNews.com lowered shares of ACADIA Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Monday. Five investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $24.70.

ACADIA Pharmaceuticals Stock Performance

NASDAQ ACAD traded down $0.32 during trading hours on Monday, reaching $17.20. The stock had a trading volume of 1,310,987 shares, compared to its average volume of 1,857,350. ACADIA Pharmaceuticals has a 52-week low of $13.40 and a 52-week high of $20.68. The stock has a market cap of $2.88 billion, a P/E ratio of 22.05 and a beta of 0.47. The stock has a fifty day moving average of $15.81 and a 200 day moving average of $17.00.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last released its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.10 by $0.01. The company had revenue of $244.32 million for the quarter, compared to the consensus estimate of $239.32 million. ACADIA Pharmaceuticals had a net margin of 13.83% and a return on equity of 25.83%. ACADIA Pharmaceuticals's revenue was up 18.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.10 EPS.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in ACAD. Vanguard Group Inc. increased its holdings in ACADIA Pharmaceuticals by 9.0% in the 1st quarter. Vanguard Group Inc. now owns 15,203,234 shares of the biopharmaceutical company's stock valued at $252,526,000 after purchasing an additional 1,255,594 shares during the last quarter. Assenagon Asset Management S.A. purchased a new position in shares of ACADIA Pharmaceuticals during the first quarter worth $60,845,000. First Trust Advisors LP boosted its position in shares of ACADIA Pharmaceuticals by 27.0% during the fourth quarter. First Trust Advisors LP now owns 2,700,125 shares of the biopharmaceutical company's stock worth $49,547,000 after buying an additional 574,251 shares during the period. SG Americas Securities LLC grew its stake in shares of ACADIA Pharmaceuticals by 380.3% in the fourth quarter. SG Americas Securities LLC now owns 2,483,731 shares of the biopharmaceutical company's stock valued at $45,576,000 after buying an additional 1,966,607 shares in the last quarter. Finally, Point72 Asset Management L.P. purchased a new stake in shares of ACADIA Pharmaceuticals in the 4th quarter valued at $40,935,000. 96.71% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, EVP Mark C. Schneyer sold 2,708 shares of the business's stock in a transaction dated Tuesday, April 8th. The shares were sold at an average price of $14.82, for a total value of $40,132.56. Following the sale, the executive vice president now directly owns 59,456 shares in the company, valued at approximately $881,137.92. The trade was a 4.36% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Elizabeth A. Garofalo sold 4,919 shares of the company's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $18.23, for a total transaction of $89,673.37. Following the completion of the transaction, the director now directly owns 17,595 shares in the company, valued at $320,756.85. The trade was a 21.85% decrease in their position. The disclosure for this sale can be found here. Insiders sold 18,994 shares of company stock valued at $313,131 in the last three months. 26.50% of the stock is currently owned by insiders.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.